Sarepta Therapeutics to Announce Third Quarter 2020 Financial Results and Recent Corporate Developments on November 5, 2020
October 29 2020 - 8:35AM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
genetic medicine for rare diseases, will report third quarter 2020
financial results after the Nasdaq Global Market closes on
Thursday, November 5, 2020. Subsequently, at 4:30 p.m. E.T., the
Company will host a conference call to discuss its third quarter
2020 financial results and to provide a corporate update.
The conference call may be accessed by dialing
(844) 534-7313 for domestic callers and (574) 990-1451 for
international callers. The passcode for the call is 9452027. Please
specify to the operator that you would like to join the "Sarepta
Third Quarter 2020 Earnings Call." The conference call will be
webcast live under the investor relations section of Sarepta's
website at www.sarepta.com and will be archived there following the
call for 90 days. Please connect to Sarepta's website several
minutes prior to the start of the broadcast to ensure adequate time
for any software download that may be necessary.
About Sarepta
TherapeuticsAt Sarepta, we are leading a revolution in
precision genetic medicine and every day is an opportunity to
change the lives of people living with rare disease. The Company
has built an impressive position in Duchenne muscular dystrophy
(DMD) and in gene therapies for limb-girdle muscular dystrophies
(LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth
(CMT), and other CNS-related disorders, with more than 40 programs
in various stages of development. The Company’s programs and
research focus span several therapeutic modalities, including RNA,
gene therapy and gene editing. For more information, please
visit www.sarepta.com or follow us on Twitter, LinkedIn,
Instagram and Facebook.
Internet Posting of
Information
We routinely post information that may be
important to investors in the 'Investors' section of our website
at www.sarepta.com. We encourage investors and potential
investors to consult our website regularly for important
information about us.
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Investors:Ian Estepan, 617-274-4052, iestepan@sarepta.com
Media:Tracy Sorrentino, 617-301-8566, tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2023 to Apr 2024